Foghorn Therapeutics Inc. expected to post a loss of 65 cents a share - Earnings Preview

Foghorn Therapeutics

31/07/2024 14:57

* Foghorn Therapeutics Inc.  FHTX.OQ   FHTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 2
(estimated) for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 7.9% increase in revenue to $6.041 million from $5.6 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Foghorn Therapeutics
Inc. is
for a loss of 65 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $14.50​, above​ its last closing price
of $6.98. ​​​

This summary was machine generated July 31 at 13:57 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)